Prime Medicine appoints Svetlana Makhni as CFO with $495K salary and 800K stock options

Filed April 16, 2026 · Period ending April 7, 2026 · ~1 min read

Key Changes

• high

  Svetlana Makhni appointed CFO effective April 16, 2026, bringing 20+ years biotech finance experience including recent CFO role at Marengo Therapeutics. CEO Allan Reine steps down as principal financial officer but continues as CEO.

  Item 5.02 verify on EDGAR →
• high

  Board granted Makhni stock options for 800,000 shares (4-year vest: 25% at year one, monthly thereafter) plus 100,000 performance-based options. Exercise price set at grant date closing price on Nasdaq.

  Item 5.02 verify on EDGAR →
• medium

  Compensation package includes $495,000 base salary, $40,000 sign-on bonus, and 40% target annual bonus (approximately $198,000). Total first-year cash compensation around $733,000.

  Item 5.02 verify on EDGAR →